期刊文献+

C35蛋白在乳腺癌组织中的表达及临床意义 被引量:5

Study on the expression of C35 gene and its clinical significance
原文传递
导出
摘要 目的通过检测C35蛋白在乳腺癌及正常乳腺组织中的表达,揭示C35蛋白在乳腺癌发生、发展、侵袭转移过程中的作用和意义。方法收集68例女性乳腺癌组织及20例乳腺正常组织,应用免疫组化技术检测分析C35蛋白在乳腺癌组织中的表达及其与乳腺癌临床病理特征的关系;分析乳腺癌组织C35蛋白表达与ER、PR、HER-2蛋白表达的相关性及与肿瘤不同分子亚型的关系。结果 1)乳腺癌组织中C35蛋白的表达显著高于正常乳腺组织(P<0.05),而在正常乳腺组织C35蛋白呈现低表达或不表达。C35蛋白表达与乳腺癌组织临床病理学特点存在相关性,随着乳腺癌组织的临床TNM分期、病理组织学分级的增加,C35蛋白阳性率显著升高(P<0.05);2)乳腺癌组织C35蛋白表达与ER与PR的表达呈负相关(r分别为-0.035和-0.083),与HER-2蛋白的表达呈正相关(r=0.207);3)C35在乳腺癌不同分子亚型中的阳性率差异无统计学意义(P>0.05),有无淋巴结转移者C35蛋白阳性率差异有统计学意义(P<0.05)。结论 C35蛋白在乳腺癌细胞中广泛存在,并与乳腺癌的发生、发展及预后有关,因而可作为乳腺癌诊断和治疗的标志物或新靶点。 Objective To detect the expression of C35 protein in breast cancer and normal breast tissues, reveal the occurrence, C35 protein in breast cancer development, invasion and meaning transfer process. Methods 68 cases of breast carcinoma and 20 cases of normal breast tissue, immunohistochemical staining was used to detect the expression of C35 protein in breast cancer tissues and its relationship with the clinical pathological characteristics of breast cancer; analysis of the relationship between the expression of C35 protein in breast cancer tissues and ER, PR, HER-2 protein expression and its correlation with tumor molecular subtypes. Results 1) the expression of C35 protein in breast cancer tissues was significantly higher than that in normal breast tissue (P〈 0. 05), and in the C35 protein in normal breast tissue showed low expression or no expression. Correlation characteristics and clinical pathology in breast cancer tissue C35 pro tein expression, with the increase of clinical TNM in breast cancer staging, histological grade, positive rate of C35 protein was significantly increased (P〈 0.05) ; 2) C35 protein in breast cancer tissue expression was negatively correlated with the expression of ER and PR (R respectively for -0. 035 and -0. 083), and HER-2 expression was positively related to protein (r=0. 207); 3) had no significant difference between the positive rate of C35 in breast cancer with different molecular subtypes of (P〈 0.05), there is no node difference in positive rate of C35 protein in lymph metastasis were statistically significant (P〈 0.05). Conclusion C35 protein existed in breast cancer cells, and the occurrence, development and prognosis associated with breast cancer, which may be used as a marker of diagnosis and treatment of breast cancer and a new target.
出处 《中国病原生物学杂志》 CSCD 北大核心 2013年第6期551-555,共5页 Journal of Pathogen Biology
基金 国家自然科学基金项目(No.81041075)
关键词 乳腺癌 C35蛋白 表达 免疫组化技术 Breast cancer C35 protein expression immunohistochemistry
  • 相关文献

参考文献9

  • 1Zheng G,Peng F,Ding R,et al.Identification of proteins re-sponsible for the multiple drug resistance in 5-fluorouracil-inducedbreast cancer cell using proteomics analysis[J].J Cancer Res ClinOncol,2010,136(10):1477-88. 被引量:1
  • 2Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of hu-man breast tumors[J].Nature,2000,406(6797):747-52. 被引量:1
  • 3Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science,1987,235 :177-82. 被引量:1
  • 4Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastu-zumab after adjuvant chemotherapy in HER2-positive breastcancer[J]. N Engl J Med,2005-353 :1659-72. 被引量:1
  • 5Ward S,Pilgrim H,Hind D.Trastuzumab for the treatment ofprimary breast cancer in H ER2-positive women:a single tech-nology appraisal [J].Health Technol Assess,2009,13(Suppl1):1-6. 被引量:1
  • 6Ghayad SE,Vendrell JA,Larbi SB,et al.Endocrine resistanceassociated with activated ErbB system in breast cancer cells is re-versed by inhibiting MAPK or PI3K/Akt signaling pathways[J].Int J Cancer,2010,126 :545-62. 被引量:1
  • 7Evans EE,Henn AD,Jonason A,et al,C35(C17orf37)is a no-vel tumor biomarker abundantly expressed in breast cancer[J],Mol Cancer Ther,2006,5:2919-30. 被引量:1
  • 8Dasgupta S,Wasson LM,Rauniyar N,et al.Novel geneC17orf37 in 17ql2 amplicon promotes migration and invasion ofprost at e cancer cells[J],Oncogene,2009,28:2860-72. 被引量:1
  • 9Evans EE,Henn AD,Jonason A,et al.C35(C17orf37)is a no-vel tumor biomarker abundantly expressed in breast cancer[J].Mol Cancer Ther,2006,5 :2919-30. 被引量:1

同被引文献52

  • 1宋依凝,魏敏杰,金万宝.乳腺癌易感基因(BRCA)的生物学功能与临床意义[J].现代肿瘤医学,2008,16(11):1992-1994. 被引量:11
  • 2付欣鸽,王振华,李锋,胡文浩,米开.热木,蒋金芳,李洪安.110例维吾尔族及汉族乳腺癌中BRCA1基因突变及P53蛋白表达的研究[J].中国组织化学与细胞化学杂志,2007,16(3):340-346. 被引量:6
  • 3EVANS EE, HENN A D, JONASON A, et al. C35 (C17ori37) isa novel tumor biomarker abundantly expressed in breast cancer[J]. Mol Cancer Ther, 2006, 5(11): 2919-2930. 被引量:1
  • 4DASGUPTA S,WASSON LM,RAUNIYAR N, et al. Novel geneC17 or .37 in 17ql2 amplicon promotes migration and invasionof prostate cancer cells[J]. Oncogene, 2009, 28(32): 2860-2872. 被引量:1
  • 5KAUFMANN M,VON MINCKW1TZ G, BEAR HD, et al. Rec-ommendations from an international expert panel on the use ofneoadjuvant (primary) systemic treatment of operable breast can-cer: new per-spectives 2006 [J]. Ann Oncol, 2007, 18 (12):1927-1934. 被引量:1
  • 6WOLFF AC, HAMMOND ME,SCHWARTZ JN, et al. AmericanSociety of Clinical Oncology/College of American Pathologistsguideline recommendations for human epidermal growth factor re-ceptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 131(1):18-43. 被引量:1
  • 7BANG Y, CHUNG H, XU J, et al. Pathological features of ad-vanced gastric cancer (GC): relationship to human epidermalgrowth factor receptor2 (HER2) positivity in the global screeningprogramme of the ToGA trial [J]. Journal of Clinical Oncology,2009, 27(15S): 4556. 被引量:1
  • 8NICHOLAS G, CRIPPS C, AU HJ, et al. Early results of a trialof trastuzumab, cisplatin and docetaxel for the treatment ofmetastatic gastric cancer overexpressing HER2 [C]. Istanbul: ES-MO, 2006. 被引量:1
  • 9VALABREGA G, MONTEMURRO F,AGUETTA M. Trastuzum-ab: mechanism of action, resistance and future perspectives inHER2-overexpressing breast cancer [J]. Ann Oncol, 2007, 18(6):977-984. 被引量:1
  • 10UNDERHILL D M, GOOD RIDGE HS. The many faces of ITAMs[J]. Trends Immunol, 2007, 28(2): 66-73. 被引量:1

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部